Ganeden Receives Bacillus Coagulans Patent

CLEVELAND — Ganeden Biotech received a new patent which covers probiotic Bacillus coagulans in all coffee, tea and cereal including GanedenBC30 (U.S. Patent #8,697,055 B2).

"Our patent attorneys at Mintz Levin continue to provide superior legal counsel that strengthens our market position," said David Keller, Ganeden Biotech VP of scientific operations.

Ganeden Biotech makes probiotics in functional food form to provide consumers with an alternative to supplement pills. 

Spore-forming probiotic organisms such as GanedenBC30 can withstand harsh manufacturing processes, especially those required to make hot tea, coffee and cereal, and protects the genetic core of the bacteria throughout the manufacturing process and the transit in to the gut. Non-spore-forming probiotics, such as Lactobacillus and Bifidobacterium, are unable to form this protective layer, making them much more vulnerable to manufacturing conditions, Ganeden said.

GanedenBC30 was announced in February to be the only probiotic to survive high pressure pasteurization (HPP).

"This patent goes a long way toward supporting our partners in their quest to launch new brands, and revolutionize existing ones," said Andy Lefkowitz, CEO of Ganeden Biotech. "When combined with the FDA's No Objection letter on GRAS (generally regarded as safe), 17 studies published in peer reviewed journals, over 100 patents issued around the world and the pending issuance of the first monograph by the USP, we have again demonstrated our commitment to science-based probiotic innovation."